Strengthening Expertise at Epitopea
In an exciting development for the field of cancer immunotherapy, Epitopea recently announced the appointment of four eminent experts to its Scientific Advisory Board (SAB). These experts are recognized leaders in immuno-oncology, translational research, and vaccine development, and their contributions are expected to significantly support Epitopea in advancing its unique Cryptigen™-targeting immunotherapies.
Meet the New Members of the SAB
Dr. Nahum Sonenberg
Dr. Nahum Sonenberg holds the position of James McGill Professor at McGill University. He is recognized globally for his work on translational control in health and disease, particularly his pioneering discovery of the mRNA 5' cap-binding protein eIF4E. His research has identified crucial links between translational control mechanisms and various diseases, including cancer. Prof. Sonenberg’s accolades include membership in prestigious scientific societies and awards like the Gairdner International Award.
Reflecting on his new role, Prof. Sonenberg remarked, "Joining Epitopea's SAB presents an exciting opportunity to apply my background in translational control to foster advancements in cancer immunotherapy. The focus on Cryptigen™ tumor-specific antigens is particularly compelling and grounded in groundbreaking research."
Dr. Nina Bhardwaj
Joining Dr. Sonenberg is Dr. Nina Bhardwaj, a prominent figure at the Icahn School of Medicine at Mount Sinai, where she serves as a Professor and the Director of Immunotherapy. She has developed innovative vaccines based on dendritic cell strategies and has led significant research in the field. Dr. Bhardwaj's extensive list of publications and prestigious awards highlights her influence and contributions to cancer immunology.
Dr. Bhardwaj expressed her enthusiasm about the initiative, saying, "I am eager to contribute to Epitopea’s mission, as targeting Cryptigen™ antigens could lead to transformative treatment options for cancer patients."
Advancing Cancer Immunotherapy Research
Dr. Margaret Callahan
Dr. Margaret Callahan serves as a Professor of Medicine and Immunology at UConn Health, focusing on immuno-oncology research to enhance patient care through innovative therapies. Her experience in clinical trial design has consistently translated laboratory successes into practical treatment options.
Dr. Callahan stated, "My passion as a physician scientist drives me to bridge promising scientific findings into real-world therapies. I see immense potential in Epitopea's platforms to provide better treatment avenues for patients."
Dr. Craig L. Slingluff, Jr.
Dr. Craig L. Slingluff, Jr. is a Professor of Surgery at the University of Virginia and has dedicated his research to melanoma immunology and cancer vaccine development. His work is instrumental in optimizing vaccines and integrating innovative treatments to improve patient outcomes. Dr. Slingluff highlights his commitment to training future scientists, merging research with clinical practice.
Expressing his excitement about joining the SAB, Dr. Slingluff shared, "Building new pathways in cancer vaccine research through Epitopea’s innovative strategies represents an important evolution in our approach to treatment."
The Importance of Collaboration
Jon Moore, PhD, Chief Scientific Officer at Epitopea, remarked: "We are thrilled to welcome such an extraordinary group to our Scientific Advisory Board. Their cumulative experiences and proven track records will serve as a guiding light as we transition our Cryptigen™ discoveries into practical, accessible immunotherapies aimed at treating challenging cancers."
This expansion of Epitopea’s Scientific Advisory Board emphasizes the company’s dedication to enhancing its scientific foundation, which is crucial for the clinical development of its RNA-based cancer immunotherapies.
About Epitopea
Epitopea is paving the way in cancer immunotherapy solutions, focusing on RNA-based therapies that are accessible and off-the-shelf. Their approach targets a new class of tumor-specific antigens, namely Cryptigen™ TSAs, which are capable of being utilized in various patients suffering from similar tumor types. Their innovative CryptoMap™ platform continues to unveil novel TSAs, revealing untapped potential within cancer's genetic makeup and expanding the possibilities for effective treatments.
Backed by premier life science investors, Epitopea's collaborative efforts exemplify dedication to innovation and therapeutic advancement in the fight against cancer.
Frequently Asked Questions
Who are the new appointees on Epitopea's Scientific Advisory Board?
The new members are Dr. Nahum Sonenberg, Dr. Nina Bhardwaj, Dr. Margaret Callahan, and Dr. Craig L. Slingluff, Jr.
What is Epitopea focusing on with their new immunotherapy research?
Epitopea is developing RNA-based immunotherapies that target a class of tumor-specific antigens called Cryptigen™ TSAs.
What are the credentials of Dr. Nahum Sonenberg?
Dr. Sonenberg is a globally recognized expert in translational control, with numerous prestigious awards and fellowships to his name.
How does Dr. Nina Bhardwaj contribute to cancer research?
Dr. Bhardwaj specializes in dendritic cell biology and has created effective cancer vaccines.
What is the goal of Epitopea's new collaborations?
The goal is to enhance the development of off-the-shelf immunotherapies for patients with hard-to-treat cancers.
